Table II.
Cumulative prevalence of severe prurigo nodularis (PN) for patients treated with topical corticosteroids, groups II–IV 2015–2020, ≥ 18 years old
| Item | No. severe PNa | No. total | Severe PN per 100,000 | Percentage of all with PN+topical corticosteroids | p-value* |
|---|---|---|---|---|---|
| All | 1,481 | 6,611,040 | 22.4 | 47.2 | |
| Sex | 0.17 | ||||
| Male | 628 | 2,920,935 | 21.5 | 46.0 | |
| Female | 853 | 3,690,105 | 23.1 | 48.2 | |
| Comorbid AD | < 0.001 | ||||
| Non-AD | 287 | 5,354,972 | 5.4 | 50.9 | |
| AD | 1,194 | 1,256,068 | 95.1 | 46.4 | |
| Age groups | < 0.001 | ||||
| 18–39 | 90 | 2,117,681 | 4.2 | 43.7 | |
| 40–59 | 323 | 1,973,528 | 16.4 | 43.6 | |
| 60–79 | 752 | 1,987,286 | 37.8 | 47.7 | |
| 80+ | 316 | 532,545 | 59.3 | 51.7 |
a
Defined as having treatment with any of the following systemic treatments or any combination of the treatments: oral corticosteroids, cyclosporine, or gabapentinoids using the ATC codes L04AD01, N03AX12, N03AX16, H02AB01, H02AB06, H02AB07, H02AB08, D11AH05, L04AX03, L04AX02, L04AX04, L04AA06. Only individuals with groups II–IV topical treatment with corticosteroids are included. Individuals with last treatment before first PN diagnosis are not included as severe PN. For individuals with severe PN in 2015, topical treatment was also included if that occurred in the year 2014.
*
χ2 test, prevalence.